the mechanism by which the atypical antipsychotics (APs) improve psychosis with a "minimum" of extrapyramidal side effects (EPSEs) is thoughtprovoking (1) . Nevertheless, important observations remain unexplained. For example, according to this hypothesis, amoxapine should be atypical; however, it is not-at least, not in Parkinson's disease (PD) patients (2) . Pimozide, which is most similar clinically to haloperidol in terms of EPSEs, should in theory be more atypical than risperidone. Olanzapine, which certainly worsens parkinsonism in PD patients (thus illustrating its extrapyramidal effects), has very little effect on prolactin levels, in contrast to risperidone and the typicals. According to their D 2 binding, molindone and loxapine should be more atypical than risperidone, yet they seem to lack any special benefits other than those previously accorded to low-potency neuroleptics. Perhaps most intriguing is the observation that olanzapine treatment, which PD patients tolerate poorly owing to motor dysfunction, is virtually free from acute dystonic reactions-a property shared by quetiapine and clozapine, but not by risperidone.
Significant conflicting reports complicate efforts to interpret the EPSEs of these drugs, with studies reporting either major or no parkinsonism from olanzapine and risperidone (3) . One study even reports that, when compared, neuroleptic-naïve young patients receiving equal dosages of either risperidone or haloperidol showed no differences in parkinsonism, acute dystonia, and akathisia (4).
While the "fast-off-D 2 " theory may be important, it does not completely explain the effects of the atypical APs, which all act on a myriad of neurotransmitters. The suggestion that thioridazine may be "relatively free" of EPSEs is speculative and, if true, not clearly related to its anticholinergic properties. There are clear limits to the benefits of anticholinergics in alleviating the signs and symptoms of neuroleptic-induced parkinsonism: concurrent treatment with anticholinergics reduces, but does not eliminate, parkinsonism. Conversely, clozapine's anticholinergic action is not mirrored in systemic side effects (for example, dry mouth, constipation, blurred vision, or impaired memory). Clozapine has potent antitremor effects in PD patients, and it works in patients who failed to respond to anticholinergics at higher dosages.
It is also apparent that formulating hypotheses is limited by conflicting data on just what motor side effects these drugs have.
I close by asking about the relevance of data suggesting preferential binding of drugs in and out of the striatum. The basic principle proposed in my article (1) is that there are 2 groups of antipsychotics (APs), those that bind tightly to the dopamine D 2 receptor and those that bind more loosely to the D 2 receptor (2-4). The traditional APs, which elicit parkinsonism, bind to the dopamine D 2 receptor more tightly than does dopamine to the high-affinity state of the D 2 receptor. The newer, atypical APs, which elicit less or no parkinsonism, bind to the dopamine D 2 receptor more loosely than does dopamine to the highaffinity state of the D 2 receptor (1). APs that are more loosely bound to D 2 are able to come off the receptor more quickly, as found by human brain positron tomography with quetiapine and clozapine (4) (5) (6) (7) . This quality allows endogenous dopamine to conduct normal neurotransmission over a matter of hours.
A look at clozapine and isoclozapine, as well as loxapine and isoloxapine, supports this general principle of tightly bound and loosely bound types of APs and their relation to EPSEs. For example, clozapine and isoclozapine have identical affinities at the cloned muscarinic M 1 receptor, the dopamine D 1 and D 4 receptors, and the serotonin 1 A and 2 A receptors. However, isoclozapine has a tenfold higher affinity than clozapine for the human cloned D 2 receptor and correspondingly elicits catalepsy and hyperprolactinemia (7, 8) , in contrast to clozapine. Similarly, while loxapine and isoloxapine have similar affinities at the dopamine D 3 and D 4 receptors, and also at the 5-HT 1A and 5-HT 2A receptors, isoloxapine has a twofold-to-tenfold lower affinity for the D 2 receptor than does loxapine. As a result, isoloxapine does not lead to catalepsy or elevated prolactin (9) , in contrast to loxapine.
Despite this basic underlying principle, however, there is no sharp clinical division between typical and atypical APs: dosage-dependent parkinsonism can occur with the moderately loosely bound APs such as olanzapine. Additional factors are to be considered for each of the atypical APs, especially when discussing the action of APs for L-DOPA psychosis in Parkinson's disease patients, as Dr Friedman properly points out. For example, Dr Friedman notes that amoxapine, with its high dissociation constant of 20 nM (1), ought to be an atypical AP-as in fact it is for patients with schizophrenia (S Kapur, personal communication, 1999), but not for patients with Parkinson's disease (10) . As outlined previously (1), the Parkinson putamen has only 2% or 3% of the normal amount of dopamine (11) , and Parkinson's disease patients with L-DOPA psychosis should in principle receive one-thirtieth the dosage of an atypical AP given to patients with schizophrenia. Because the recommended AP dosage of amoxapine is 150 to 250 mg daily (12), the starting dosage for Parkinson's disease subjects ought, a priori, to be about 6 mg daily. However, the amoxapine starting dosage was 12.5 mg daily for the 3 patients tested by Sa and others (10) . Although APs with dissociation constants between 2 and 20 nM can elicit dosage-dependent parkinsonism, the dissociation speed of the radiolabelled AP best predicts whether an AP will be atypical. While it has been directly determined that Molindone and loxapine have dissociation constants in the range of 2 nM to 20 nM for D 2 and thus elicit dosagedependent parkinsonism (1).
As for thioridazine, this compound has repeatedly been observed to cause fewer EPSEs (18, 19) . Concerning the anticholinergic effects of thioridazine and clozapine, these drugs have the same potent affinity as benztropine for the M 1 muscarinic-cholinergic receptor (that is, dissociation constants of 3 nM) (20, 21) . Hence, clinical dosages of 200 to 400 mg daily of clozapine or thioridazine are equivalent to giving a patient one hundredfold more of the customary benztropine dosage of 2 mg twice daily. It is not surprising, therefore, that clozapine would be clinically more effective than benztropine in alleviating parkinsonism.
As for the absence of systemic side effects with clozapine (that is, dry mouth and blurred vision, although clozapine does cause constipation), it is known that clozapine is a potent agonist at the M 4 muscarinic receptor (22) . This agonist action may underly clozapine-induced hypersalivation and the absence of systemic anticholinergic effects. In addition, because clozapine has a tenfold range of different affinities for the 5 different muscarinic receptors (21, 22) , the receptor basis for the clinical cholinergic and anticholinergic actions of clozapine is not obvious.
On the question of relevance of data for drugs binding in and out of the striatum, the D 2 percentage occupancy by a drug in the striatum is generally identical to, or slightly lower than, the D 2 occupancy for nonstriatal brain regions, such as the cingulate cortex (23, 24 Recently, I have seen 2 cases in which patients were diagnosed and treated for BD after being treated for other diagnosed disorders. In each case, their conditions worsened.
Case Report 1
Mrs A is married, in early middle age, and has 2 teenaged children. She was admitted to hospital and diagnosed with unipolar depression, together with some long-standing personality and family problems. She responded poorly to treatment, was discharged with mild improvement, and readmitted soon after. On readmission, her treating psychiatrist undertook a detailed review of her history, rediagnosed her with BD, and treated her with divalproex. She was told the diagnosis. She seemed to improve rapidly, and was discharged home. In follow-up for the next few months, her self-report was very good and she was very pleased with the psychiatrist for taking the time to reassess her and find the "correct" diagnosis. Then, one of her daughters attempted suicide, giving as a reason the fact that her mother had no time for her because she was spending all her time on a BD Internet chat line. After this, the patient was no longer pleased with her psychiatrist and was lost to follow-up.
Case Report 2
When she presented for treatment, Mrs B, also middle-aged, was in a second, quite supportive marriage. She had a history of an abusive first marriage and severe dysfunction during her childhood. She had left that marriage, taken a college course that interested her, obtained a diploma, and obtained appropriate work.
She quickly found her work too stressful, largely because it reminded her of things in her past that caused a recurrence of posttraumatic stress disorder (PTSD) symptoms. When she presented for treatment, she was diagnosed with unipolar depression, generalized anxiety disorder, and subsyndromal PTSD symptoms. She did not respond well to treatment and was unable to return to work after a period of many months. She and her husband then decided to seek assessment and treatment from a different psychiatrist, with the original psychiatrist's agreement. She was diagnosed with BD, started on divalproex, and discharged. A few months later, she presented to her original psychiatrist. She said that on divalproex she had felt "totally flat" and refused to live that way. She had therefore discontinued it, and her former symptoms all promptly recurred. Her psychiatrist told her that he did not agree with the diagnosis of BD but had no new treatment to offer her, other than a trial of different antidepressant medication. She accepted that and also learned to accept that she was not able to work in her chosen field. She subsequently improved moderately.
I suggest that there may be as much danger in overdiagnosing as in underdiagnosing BD.
